Your session is about to expire
← Back to Search
Understanding Clinician Utilization of Corus CAD (Age/Sex/Gene Expression Score - ASGES) in Clinical Decision Making (UCU-CARD Trial)
N/A
Waitlist Available
Led By David Hoffman, DO
Research Sponsored by CardioDx
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 24 months
Awards & highlights
No Placebo-Only Group
Summary
The purpose of this study is to understand the use of Corus CAD also known as Age/Sex/Gene Expression score (ASGES) in the clinical decision making process of patients who underwent the evaluation of chest pain or anginal equivalent symptoms. Specifically, to better understand whether the use of the assay in clinical decision making resulted in changes in noninvasive diagnostic test ordering or diagnostic yield of additional tests ordered and/or invasive angiography.
Eligible Conditions
- Angina
- Congenital heart disease
- Cardiovascular Disease
- Coronary Artery Disease
- Chest Pain
- Coronary Heart Disease
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 24 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 24 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
The primary measure of this study is the number of advanced diagnostic tests in ASGES (treatment group) patients compared to the number of advanced diagnostic tests in non-ASGES (control group) patients.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Group I: Non-ASGES (Control Group)Experimental Treatment0 Interventions
Patients who underwent usual care testing and did not receive a Corus CAD or Age/SEX/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
Group II: ASGES (Treatment Group)Experimental Treatment1 Intervention
Patients who received a Corus CAD or Age/Sex/Gene Expression Score (ASGES) to aid in the diagnosis of obstructive CAD
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Corus CAD
2013
N/A
~810
Find a Location
Who is running the clinical trial?
CardioDxLead Sponsor
12 Previous Clinical Trials
9,096 Total Patients Enrolled
David Hoffman, DOPrincipal InvestigatorNortheast Ohio Medical University
Jaime Burkle, MDPrincipal InvestigatorPiedmont Heart Institute
Lawrence Kline, DPPrincipal InvestigatorJohn C. Lincoln Heart Institute